CLASS II Drug recall · Reported 25 Jan 2023 · FDA Enforcement Report

Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection recalled

Fresenius Kabi USA is recalling Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200, distributed nationwide in the US. The recall was initiated on 22 Nov 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesBatch #: 6128800, exp 12/2023
NDC63323-461, 63323-472, 63323-463, 63323-468
UPC0363323472030, 0363323461010, 0363323463014, 0363323468026, 0363323472016, 0363323468019
Quantity recalled31,600 vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0129-2023
FDA event ID
91198
Recalling firm
Fresenius Kabi USA, Lake Zurich, IL
Manufacturer
Fresenius Kabi USA, LLC
Classification
Class II
Status
Terminated
Recall initiated
22 Nov 2022
FDA classified
13 Jan 2023
Reported
25 Jan 2023
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

22 Nov 2022Recall initiated by company
13 Jan 2023Classified by FDA+52 days
25 Jan 2023Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200,000 (as bitartrate), 0.25%, 25 mg per 10 mL (2.5 mg per mL), 10 mL Single Dose Vial (NDC 63323-468-01), packaged in 25 Single Dose Vials per tray (NDC 63323-468-17), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Is Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200 recalled?

Yes. Fresenius Kabi USA recalled Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine 1:200 on 22 Nov 2022. The recall is Class II and its status is Terminated. Recall number D-0129-2023.

Why was it recalled?

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Which lots are affected?

Batch #: 6128800, exp 12/2023

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Fresenius Kabi USA

All 94

Other Bupivacaine Hydrochloride recalls

All 5